Nigeria has officially acquired Lenacapavir, an innovative long-acting injection for preventing HIV, marking a pivotal advancement in the nation’s battle against the HIV epidemic. The approval for this breakthrough drug was granted by the Coordinating Minister of Health and Social Welfare, Ali Pate, with backing from the Global Fund.
Lenacapavir is formulated for pre-exposure prophylaxis (PrEP), serving as an alternative to the regular daily oral options for HIV prevention. This injectable treatment is administered biannually, offering at-risk individuals a more convenient choice compared to the daily regimen of medication.
Health professionals believe that this new injection could notably enhance treatment adherence, especially for those who struggle to maintain a daily medication schedule.
Adebobola Bashorun, the National Coordinator of the National HIV Viral Hepatitis and STDs Control Programme (NASCP), emphasized that the introduction of Lenacapavir underscores Nigeria’s dedication to adopting evidence-based innovations to quicken progress towards managing the epidemic.
He further noted that broadening prevention options and enhancing service delivery are vital for minimizing new infections and advancing health outcomes nationwide. Bashorun assured that NASCP, in collaboration with partners and stakeholders, will oversee the safe deployment and effective integration of Lenacapavir into the country’s national HIV prevention strategies.
Lenacapavir is set to be accessible in Nigeria and 119 other low- and middle- income nations at an estimated annual cost of roughly $40 per individual, facilitated by voluntary licensing agreements with generic drug manufacturers.
Health officials assert that the launch of this long-acting injection brings Nigeria closer to its aim of eliminating HIV as a public health concern.
Comments (0)
You must be logged in to comment.
Be the first to comment on this article!